Amgen Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31)
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) of -$21.00 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecrease · last filed 2012-02-29
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2011 was -$21.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2010 was -$55.00M, a 175.34% decline from fiscal 2009.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2009 was $73.00M.
- Amgen Inc. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2008 was -$60.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | -$21.00M 10-K · filed 2012-02-29 |
| 2010-12-31 | -$55.00M 10-K · filed 2012-02-29 |
| 2009-12-31 | $73.00M 10-K · filed 2012-02-29 |
| 2008-12-31 | -$60.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |